Shenzhen - Delayed Quote CNY

Shanghai RAAS Blood Products Co., Ltd. (002252.SZ)

7.19 -0.07 (-0.96%)
At close: April 26 at 3:04 PM GMT+8
Key Events
Loading Chart for 002252.SZ
DELL
  • Previous Close 7.26
  • Open 6.95
  • Bid 7.18 x --
  • Ask 7.19 x --
  • Day's Range 7.15 - 7.28
  • 52 Week Range 5.93 - 8.68
  • Volume 32,985,570
  • Avg. Volume 35,528,434
  • Market Cap (intraday) 47.781B
  • Beta (5Y Monthly) 0.43
  • PE Ratio (TTM) 23.19
  • EPS (TTM) 0.31
  • Earnings Date --
  • Forward Dividend & Yield 0.03 (0.42%)
  • Ex-Dividend Date Jun 13, 2023
  • 1y Target Est --

Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human thrombin and human fibrin adhesive, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. Shanghai RAAS Blood Products Co., Ltd. was founded in 1988 and is based in Shanghai, China.

www.raas-corp.com

3,121

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 002252.SZ

Performance Overview: 002252.SZ

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

002252.SZ
10.12%
SSE Composite Index
3.82%

1-Year Return

002252.SZ
17.03%
SSE Composite Index
5.40%

3-Year Return

002252.SZ
7.27%
SSE Composite Index
11.10%

5-Year Return

002252.SZ
20.89%
SSE Composite Index
1.13%

Compare To: 002252.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 002252.SZ

Valuation Measures

Annual
As of 4/28/2024
  • Market Cap

    47.78B

  • Enterprise Value

    43.55B

  • Trailing P/E

    23.34

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.38

  • Price/Book (mrq)

    1.60

  • Enterprise Value/Revenue

    5.77

  • Enterprise Value/EBITDA

    17.55

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    27.33%

  • Return on Assets (ttm)

    4.43%

  • Return on Equity (ttm)

    7.03%

  • Revenue (ttm)

    7.55B

  • Net Income Avi to Common (ttm)

    2.06B

  • Diluted EPS (ttm)

    0.31

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.24B

  • Total Debt/Equity (mrq)

    0.01%

  • Levered Free Cash Flow (ttm)

    2.14B

Research Analysis: 002252.SZ

Analyst Price Targets

 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Company Insights: 002252.SZ

People Also Watch